James Peyer is Director & 10% Owner at Sensei Biotherapeutics, Inc. (SNSE). They have made 48 open-market trades across 1 company since 2021, most recently 2026-06-01.
CIK 0001843594
45 open-market purchases totalling $5.7M since 2021, against 3 sales. Across 45 scored buys the stock is down 42.6% at ninety days, and 42.8 points behind the S&P over the same stretch.
45 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| SNSE | 130,142 | $1.8M |
Shares reported on the most recent Form 4, priced at the 2026-06-01 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 18% | 2% | 4% |
| Avg Move | -7.0% | -18.9% | -42.6% |
| Alpha | -6.7% | -19.0% | -42.8% |
| Scored | 45 | 45 | 45 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SNSE | SELL | 2026-06-01 | 2026-06-01 | $20.02 | $501K | -43.8% | N/A | N/A |
| SNSE | SELL | 2025-12-08 | 2025-12-10 | $8.25 | $55K | +18.2% | +44.1% | +272.2% |
| SNSE | SELL | 2025-12-04 | 2025-12-08 | $11.12 | $398K | +9.5% | +34.7% | +254.1% |
| SNSE | BUY | 2022-03-02 | 2022-03-02 | $3.20 | $4K | -20.2% | -32.0% | -42.6% |
| SNSE | BUY | 2022-02-28 | 2022-03-01 | $3.60 | $9K | -23.9% | -34.9% | -46.5% |
| SNSE | BUY | 2022-02-25 | 2022-02-28 | $3.65 | $9K | -17.0% | -36.2% | -47.9% |
| SNSE | BUY | 2022-02-23 | 2022-02-24 | $3.65 | $64K | -17.2% | -40.1% | -56.2% |
| SNSE | BUY | 2022-02-17 | 2022-02-22 | $4.02 | $80K | -19.3% | -34.3% | -57.5% |
| SNSE | BUY | 2022-02-14 | 2022-02-16 | $4.19 | $53K | -16.4% | -33.4% | -59.7% |
| SNSE | BUY | 2022-02-10 | 2022-02-14 | $4.43 | $133K | -9.4% | -37.3% | -61.4% |
| SNSE | BUY | 2022-02-03 | 2022-02-08 | $4.53 | $136K | -6.8% | -31.3% | -65.3% |
| SNSE | BUY | 2022-01-27 | 2022-01-31 | $4.26 | $64K | -3.4% | -28.1% | -65.5% |
| SNSE | BUY | 2022-01-25 | 2022-01-27 | $4.72 | $236K | +0.0% | -16.0% | -61.6% |
| SNSE | BUY | 2022-01-21 | 2022-01-25 | $4.82 | $457K | -6.0% | -24.3% | -62.3% |
| SNSE | BUY | 2022-01-19 | 2022-01-21 | $5.07 | $205K | +2.5% | -19.8% | -61.7% |
| SNSE | BUY | 2022-01-18 | 2022-01-20 | $5.08 | $51K | -1.6% | -23.8% | -61.8% |
| SNSE | BUY | 2022-01-13 | 2022-01-18 | $5.11 | $236K | -12.5% | -20.7% | -63.1% |
| SNSE | BUY | 2022-01-11 | 2022-01-13 | $5.19 | $160K | -13.3% | -18.9% | -59.2% |
| SNSE | BUY | 2022-01-10 | 2022-01-11 | $5.28 | $53K | -8.1% | -16.5% | -61.7% |
| SNSE | BUY | 2021-12-30 | 2022-01-03 | $4.85 | $5K | -16.8% | -19.1% | -63.2% |
| SNSE | BUY | 2021-12-29 | 2021-12-30 | $4.98 | $687K | -2.0% | -12.4% | -57.6% |
| SNSE | BUY | 2021-12-28 | 2021-12-29 | $5.28 | $119K | +8.9% | -6.6% | -54.2% |
| SNSE | BUY | 2021-12-27 | 2021-12-27 | $5.30 | $20K | +2.8% | -19.4% | -58.7% |
| SNSE | BUY | 2021-12-23 | 2021-12-23 | $5.27 | $116K | -1.4% | -12.8% | -56.8% |
| SNSE | BUY | 2021-12-17 | 2021-12-21 | $5.29 | $619 | +7.2% | -9.7% | -55.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.